Google
APM — APTORUM GROUP LTD CLASS A (Healthcare >> Biotechnology)
APM FAQ
What is APM's ROE?
APTORUM GROUP LTD CLASS A reports a Return on Equity (ROE) of -14.25%.
What is APM's dividend yield?
APTORUM GROUP LTD CLASS A offers a dividend yield of 0.00%.
What is APM's Deepscope Quality Score?
Deepscope rates APM's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy APM?
Deepscope's AI Timing Score for APM is 3 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does APM belong to?
APTORUM GROUP LTD CLASS A is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 0.98
Price
-0.09
(-8.79%)
Day Change
|
|
|---|
APM, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
ROEが昨年度比で低い
ROAがROEに比べて低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.98 |
| PBV / Sector |
0.63 / 4.53
GREAT
|
| Earning Per Share | -0.37 |
| PE / Sector |
N/A / 16.80
|
| PEG or PE/Growth / Sector |
N/A / 0.51
|
| Average 1M Daily Value |
0.07 M
GREAT
|
| Average 1W Daily Value |
0.22 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
43% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-03 09:11:17 |
| Symbol | APM |
| Name | APTORUM GROUP LTD CLASS A |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 6.35 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 8.71 / 8,614.17 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 17 Hanover Square, London, United Kingdom, W1S 1BN
Phone: 44 20 8092 9299
Website: https://www.aptorumgroup.com
Sector: Healthcare >> Biotechnology
Description: Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa. The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule which is in preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule which is in preclinical trial for the treatment of gram+ve bacterial infections. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
